The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Cordis EMPIRA™ and EMPIRA™ NC RX PTCA Dilatation Catheters Receive FDA Clearance

<p class='bwalignc'> <i>US Launch Expected in Early 2012</i> </p>

Tuesday, November 08, 2011

Cordis EMPIRA™ and EMPIRA™ NC RX PTCA Dilatation Catheters Receive FDA Clearance19:26 EST Tuesday, November 08, 2011 SAN FRANCISCO (Business Wire) -- Cordis Corporation today announced EMPIRA™ and EMPIRA™ NC RX PTCA Dilatation Catheters have received 510(k) regulatory clearance for the treatment of coronary artery disease. The EMPIRA™ Balloon Catheters are used in angioplasty procedures and are designed to enable interventional cardiologists to open patients' narrowed coronary arteries. The family of EMPIRA™ Balloon Catheters incorporates several design and technology changes that have the potential to improve crossability and recrossability, while enhancing the controlled growth characteristics of the balloon material. The semi-compliant EMPIRA™ RX PTCA Pre-Dilatation Catheter and the non-compliant EMPIRA™ NC RX PTCA Post-Dilatation Catheter utilize the next generation DURALYN® Flex balloon material, which is 50% more flexible than the DURALYN® balloon material used in the current FIRE STAR® and DURA STAR® RX PTCA Dilatation Catheters.1 These new products will become available in the USA in 2012. "The EMPIRA™ Balloon Catheters offer our most advanced technology designed to treat challenging coronary artery disease," said Campbell Rogers, MD, Cordis Chief Scientific Officer, Global Head R&D. “Cordis worked closely with our physician-customers and incorporated their feedback into the design of these next generation devices. We believe the unique design of the EMPIRA™ Balloon Catheters will meet physicians' needs and has the potential to improve patient outcomes. These products further expand the array of high quality tools we offer physicians to treat patients with coronary artery disease." About Cordis Corporation Cordis Corporation, a Johnson & Johnson company, specializes in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis works with interventional cardiologists, interventional radiologists and vascular surgeons worldwide to treat millions of patients who suffer from vascular disease. For more information about Cordis please visit: www.cordis.com (this site is intended for US visitors only). (This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Cordis Corporation and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Cordis Corporation nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) 1 Cordis Corporation. Data on file, 2011. For Cordis CorporationSandy Pound908-541-4040 office908-432-2829 mobile